Related to ViroPharma Licenses Halozyme’s Hyaluronidase for $9M to Develop Subcutaneous Cinryze

• Morphotek Acquires TransMolecular’s Tumor-Targeting Drug Delivery Assets
  
• Alnylam Extends RNAi Alliance with UBC and AlCana Technologies
  
• Scientists Develop High-Capacity Nanoparticles for Targeted Delivery of Drug Cocktails
  
• Precision NanoSystems and Alnylam Ally to Enhance RNAi Delivery
  
• Researchers Engineer Cells’ Own Vault Nanoparticles to Deliver Cytotoxic Drugs
  
• Proteostasis Therapeutics Licenses Protein Clearance Targets and Compounds from Harvard
  
• Alnylam to Test Molecular Templates’ Technology for RNAi Drug Delivery
  
• Elan Sells Drug Technologies Business to Alkermes for $960M in Cash and Shares
  
• BMS Expands Deal to Evaluate Tekmira’s RNAi Delivery Technology
  
• Radius Raises $91M for Pivotal Osteoporosis Trial and Inks Transdermal Patch Deal with 3M
  
• Defiante Takes Over Additional Territories for Marketing Dyax' HAE Drug
  
• Scientists Develop Nanoparticles Cloaked with Erythrocyte Membranes
  
• Ultragenyx Raises $45M in Series A to Progress Lead Orphan Disease Candidate into Clinic
  
• Scientists Develop Communicating Nanoparticles that Boost Targeted Drug Delivery to Tumors
  
• Digna and Flamel Partner on Drug Delivery Formulations for Multiple Candidates
  
• Tibotec and Gilead Partner to Combine HIV-1 Drugs into Single-Tablet Formulation
  
• Lotus Raises $26M in Series A to Progress Recombinant Collagen Type VII Platform
  
• Ironwood Negotiates Access to Depomed’s Upper GI Drug Delivery Technology
  
• Diamyd Shifts Development Focus from Diabetes to Pain and CNS Disorders
  
• Aura Raises $4.5M and Signs CRADA for Diagnostic and Therapeutic Nanoparticle Platform